You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
MolecularMD is expected to expand Icon's laboratory services by enabling it to better support precision medicine programs for drug-diagnostic codevelopment.
The draft guidelines have intrigued industry players interested in pursuing labeling that would allow their CDx to direct treatment for a class of drugs instead of one drug.
The firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers.
The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.
This week's news includes MolecularMD, Agendia, Promega, and NRGene.
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.
The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.
A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.
In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.